Immune-checkpoint inhibitors: long-term implications of toxicity
The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
treatment, enabling the possibility of long-term survival in patients with metastatic disease …
Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics
Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many
cancer indications. This review provides an update on ICIs approved by the Food and Drug …
cancer indications. This review provides an update on ICIs approved by the Food and Drug …
Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma
TK Choueiri, T Powles, L Albiges… - … England Journal of …, 2023 - Mass Medical Soc
Background The efficacy and safety of treatment with cabozantinib in combination with
nivolumab and ipilimumab in patients with previously untreated advanced renal-cell …
nivolumab and ipilimumab in patients with previously untreated advanced renal-cell …
Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Background Conditional survival estimates provide critical prognostic information for
patients with advanced renal cell carcinoma (aRCC). Efficacy, safety, and conditional …
patients with advanced renal cell carcinoma (aRCC). Efficacy, safety, and conditional …
[HTML][HTML] First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer …
M Reck, TE Ciuleanu, M Cobo, M Schenker… - ESMO open, 2021 - Elsevier
Background To further characterize survival benefit with first-line nivolumab plus ipilimumab
with two cycles of chemotherapy versus chemotherapy alone, we report updated data from …
with two cycles of chemotherapy versus chemotherapy alone, we report updated data from …
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
M Rosellini, A Marchetti, V Mollica, A Rizzo… - Nature Reviews …, 2023 - nature.com
The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …
immunotherapy agents by regulatory agencies. However, objective and durable responses …
Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when …
Cancer is still the leading cause of death globally. The approval of the therapeutic use of
monoclonal antibodies against immune checkpoint molecules, notably those that target the …
monoclonal antibodies against immune checkpoint molecules, notably those that target the …
[HTML][HTML] ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma
Highlights•This special article provides key recommendations on the immunotherapy
treatments of renal cell carcinoma.•Recommendations are based on available scientific data …
treatments of renal cell carcinoma.•Recommendations are based on available scientific data …
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker …
YA Vano, R Elaidi, M Bennamoun, C Chevreau… - The Lancet …, 2022 - thelancet.com
Background We previously reported a 35-gene expression classifier identifying four clear-
cell renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments …
cell renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments …
Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of …
RI Haddad, K Harrington, M Tahara… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE CheckMate 651 (ClinicalTrials. gov identifier: NCT02741570) evaluated first-line
nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus …
nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus …